John Alexander Kelly Acquires 2,113 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly acquired 2,113 shares of the firm’s stock in a transaction on Friday, December 27th. The stock was bought at an average price of $4.75 per share, with a total value of $10,036.75. Following the purchase, the chief financial officer now directly owns 40,186 shares of the company’s stock, valued at $190,883.50. This represents a 5.55 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Precision BioSciences Stock Down 8.4 %

Precision BioSciences stock opened at $4.26 on Tuesday. The company has a market capitalization of $32.68 million, a P/E ratio of 71.01 and a beta of 1.41. Precision BioSciences, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $19.43. The stock has a 50-day simple moving average of $6.79 and a 200-day simple moving average of $8.60. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22.

Hedge Funds Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC grew its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,974 shares of the company’s stock after buying an additional 19,088 shares during the quarter. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the SEC. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.